(Q48332395)

10 February 2018

title

NCT01110291: induction of CYP3A activity and lowered exposure to docetaxel in patients with primary breast cancer (English)

1 reference

https://api.crossref.org/works/10.1007/S00280-010-1426-6

2 July 2024

1 reference

Johanna Hilli

1

1 reference

10 February 2018

Liisa Sailas

2

1 reference

10 February 2018

Sirkku Jyrkkiö

3

1 reference

10 February 2018

Seppo Pyrhönen

4

1 reference

10 February 2018

Kari Laine

5

1 reference

10 February 2018

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20798939

2 July 2024

publication date

27 August 2010

1 reference

10 February 2018

full work available at URL

number of pages

10

1 reference

based on heuristic

inferred from page(s)

https://hal.archives-ouvertes.fr/hal-00617337/file/PEER_stage2_10.1007%252Fs00280-010-1426-6.pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20798939

http://link.springer.com/content/pdf/10.1007/s00280-010-1426-6.pdf

2 July 2024

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1007/S00280-010-1426-6

http://link.springer.com/article/10.1007/s00280-010-1426-6/fulltext.html

2 July 2024

1 reference

https://api.crossref.org/works/10.1007/S00280-010-1426-6

http://link.springer.com/content/pdf/10.1007/s00280-010-1426-6

2 July 2024

1 reference

https://api.crossref.org/works/10.1007/S00280-010-1426-6

Cancer Chemotherapy and Pharmacology

2 July 2024

published in

1 reference

10 February 2018

volume

67

1 reference

10 February 2018

issue

6

1 reference

10 February 2018

page(s)

1353-1362

1 reference

10 February 2018

https://scigraph.springernature.com/pub.10.1007/s00280-010-1426-6

exact match

0 references

cites work

Docetaxel for treatment of solid tumours: a systematic review of clinical data

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1426-6

Adjuvant docetaxel for node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1426-6

The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1426-6

Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1426-6

A population pharmacokinetic model for docetaxel (Taxotere): model building and validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1426-6

Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1426-6

Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1426-6

The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1426-6

Induction of cytochrome P450 3A4 by docetaxel in peripheral mononuclear cells and its expression in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1426-6

Induction of cytochrome P4503A by taxol in primary cultures of human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1426-6

A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1426-6

Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1426-6

Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1426-6

A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1426-6

Clinical pharmacodynamic factors in docetaxel toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1426-6

Phase III Trial Comparing Three Doses of Docetaxel for Second-Line Treatment of Advanced Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1426-6

Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial

21 January 2018

3

1 reference

https://api.crossref.org/works/10.1007/S00280-010-1426-6

Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver

2 July 2024

7

1 reference

https://api.crossref.org/works/10.1007/S00280-010-1426-6

Differences in the urinary excretion of 6-beta-hydroxycortisol/cortisol between Asian and Caucasian women

2 July 2024

11

1 reference

https://api.crossref.org/works/10.1007/S00280-010-1426-6

Relationship between excretion clearance of rhodamine 123 and P-glycoprotein (Pgp) expression induced by representative Pgp inducers

2 July 2024

20

1 reference

https://api.crossref.org/works/10.1007/S00280-010-1426-6

2 July 2024

Identifiers

1 reference

10 February 2018

1 reference

10 February 2018